6968-35-0

Basic information

• Product Name: 7-HYDROXY-1-INDANONE 97
• Synonyms: 7-HYDROXY-1-INDANONE 97;7-Hydroxyindan-1-one;Nsc64459;1-Oxo-7-indanol;2,3-Dihydro-7-hydroxy-1H-inden-1-one;7-Hydroxy-2,3-dihydroinden-1-one;7-Hydroxy-1-indanone 97%
• CAS NO: 6968-35-0
• Molecular Formula: C₉H₈O₂
• Molecular Weight: 148.16
• Product Categories: C9;Carbonyl Compounds;Ketones
• Mol File: 6968-35-0.mol
• Article Data: 29

Chemical Properties

• Melting Point: 109-113 °C(lit.)
• Boiling Point: 310℃
• Flash Point: 131℃
• Appearance: /Solid
• Density: 1.305
• Vapor Pressure: 0.000332mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.27±0.20(Predicted)
• CAS DataBase Reference: 7-HYDROXY-1-INDANONE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 7-HYDROXY-1-INDANONE 97(6968-35-0)
• EPA Substance Registry System: 7-HYDROXY-1-INDANONE 97(6968-35-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 6968-35-0(Hazardous Substances Data)

Usage

General Description

7-HYDROXY-1-INDANONE 97, also known as 1-indanone-7-hydroxy, is a chemical compound with the molecular formula C9H8O2. It is a white to off-white crystalline powder that is commonly used as a building block in the synthesis of various pharmaceuticals and organic compounds. It is also used as a key intermediate in the production of dyes, perfumes, and other specialty chemicals. 7-HYDROXY-1-INDANONE 97 is known for its versatile chemical properties and is widely utilized in the research and development of new chemical compounds across various industries.

InChI:InChI=1/C9H8O2/c10-7-3-1-2-6-4-5-8(11)9(6)7/h1-3,10H,4-5H2

Upstream product

• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 937-41-7 phenyl acrylate 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 40478-49-7 3-(3-methoxyphenyl)propanoyl chloride 
• 42710-26-9 phenyl 2-bromopropionate 
• 38005-83-3 2,3-dihydro-1H-indene-1,7-diol 
• 108-95-2 phenol 
• 1606590-67-3 C₉H₈O₂ 
• 10516-71-9 3-(3-Methoxy-phenyl)-propionic acid 
• 7170-38-9 3-phenoxypropanoic acid 
• 14755-02-3 3-hydroxy-trans-cinnamic acid 
• 106-41-2 4-bromo-phenol 
• 625-36-5 2-chloropropionyl chloride 
• 7446-70-0 aluminium trichloride 

Downstream Products

• 125494-84-0 7-(phenylmethoxy)indan-1-one 
• 108197-54-2 7-Hydroxy-2-[1-p-tolyl-meth-(Z)-ylidene]-indan-1-one 
• 69676-26-2 2-benzylidene-7-hydroxy-2,3-dihydro-1H-inden-1-one 
• 93747-67-2 7-allyloxyindan-1-one 
• 58350-01-9 7-hydroxy-1-aminoindan 
• 864058-53-7 7-hydroxyindan-1-one (S,S)-stilbenediol acetal 
• 864058-51-5 7-acetoxyindan-1-one (S,S)-stilbenediol acetal 
• 864058-55-9 7-acryloyloxyindan-1-one (S,S)-stilbenediol acetal 
• 1641-41-4 4-indanol 
• 215610-84-7 2-benzyl-7-hydroxy-1-indanone 
• 215610-86-9 2-benzyl-7-(oxiranylmethoxy)-1-indanone 

Relevant articles and documents

Total Synthesis of the Schisandraceae Nortriterpenoid Rubriflordilactone A

Full details of the total synthesis of the Schisandraceae nortriterpenoid natural product rubriflordilactone A are reported. Palladium- and cobalt-catalyzed polycyclizations were employed as key strategies to construct the central pentasubstituted arene from bromoendiyne and triyne precursors. This required the independent assembly of two AB ring aldehydes for combination with a common diyne component. A number of model systems were explored to investigate these two methodologies, and also to establish routes for the installation of the challenging benzopyran and butenolide rings.

Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists

Retinoic acid receptor related orphan receptor γt (RORγt), identified as the essential functional regulator of IL-17 producing Th17 cells, is an attractive drug target for treating autoimmune diseases. Starting from the reported GSK2981278 (Phase II), we structurally modified and synthesized a series of 2H-chromone-4-one based sulfonamide derivatives as novel RORγt inverse agonists, which significantly improved their human metabolic stabilities while maintaining a potent RORγt inverse agonist profile. Efforts in reducing the lipophilicity and improving the LLE values led to the discovery of c9, which demonstrated potent RORγt inverse agonistic activity and consistent metabolic stability. During in vivo studies, oral administration of compound c9 exhibited a robust and dose-dependent inhibition of IL-17A cytokine expression and significantly lessened the skin inflammatory symptoms in the mouse imiquimod-induced skin inflammation model. Docking analysis of the binding mode revealed that c9 can suitably occupy the active pocket, and the introduction of the morpholine pyridine group can interact with Leu396, His479, and Cys393. Thus, compound c9 was selected as a preclinical compound for treating Th17-driven autoimmune diseases.

ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.